Do people want to know if they are at risk for Alzheimer’s disease?
Genetic tests exist to identify risk for the rare inherited form of early-onset Alzheimer’s disease (AD) and to predict susceptibility to the more common, late-onset form of AD, but do people want to know, and how do they react? The answers can be found in the article published in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc. The article is available free on the Genetic Testing and Molecular Biomarkers website.
“This article addresses a major disease of tremendous impact on increasing numbers of people and documents the large psychological component that physicians and genetic counselors must be ready to address.” says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida’s Genetics Institute, College of Medicine, Gainesville, FL.
In the article “To Know or Not to Know: An Update of the Literature on the Psychological and Behavioral Impact of Genetic Testing for Alzheimer Disease Risk,” B. Rahman and a team of researchers from Australia review the latest studies on whether people at risk for early-onset familial AD want to know their genetic profile and actually undertake testing, and how they tend to respond to the results. They also evaluate the attitudes of the general population and people with a family history of late-onset AD toward testing for disease risk factors and what motivates them to undergo genetic testing.
About the Journal
Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published 10 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of contents and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.
About the Publisher
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available at Mary Ann Liebert, Inc..
Mary Ann Liebert, Inc./Genetic Engineering News